1. Home >
  2. M&A >
  3. Going Private >
  4. United States >
  5. New Jersey >
  6. TPG Acquires Par Pharmaceutical Companies

M&A Deal Summary

TPG Acquires Par Pharmaceutical Companies

On July 16, 2012, private equity firm TPG acquired life science company Par Pharmaceutical Companies for 1.9B USD

Acquisition Highlights
  • This is TPG’s 26th transaction in the Life Science sector.
  • This is TPG’s 44th largest (disclosed) transaction.
  • This is TPG’s 131st transaction in the United States.
  • This is TPG’s 2nd transaction in New Jersey.
Investment Fate
  • Par Pharmaceutical Companies was sold to a publicly-traded strategic buyer in 2015 for 8.1B USD.

M&A Deal Summary
Date 2012-07-16
Target Par Pharmaceutical Companies
Sector Life Science
Buyer(s) TPG
Deal Type Going Private
Deal Value 1.9B USD
Advisor(s) J.P. Morgan Securities (Financial)
Orrick (Legal)

Target

Par Pharmaceutical Companies

Woodcliff Lake, New Jersey, United States
Par Pharma specializes in developing, licensing, manufacturing, marketing and distributing generic drugs.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

TPG

Fort Worth, Texas, United States

Investor Investor Investor Investor

Category Private Equity Firm
Founded 1992
PE ASSETS 296.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

TPG Capital is a global, mega-sized private investment firm that manages a family of funds focused on private equity, real estate, venture capital, public equity and debt investing. TPG invests in opportunities across a broad range of industries and geographies. TPG generally seeks to invest in established businesses that can benefit from the Firm's operational experience and connections. Industries of interest include consumer, retail, healthcare, industrials, digital media, natural resources, energy, real estate, technology, and software. TPG was formerly known as Texas Pacific Group and was originally established in 1992 by David Bonderman, James Coulter and William Price. The Firm is based in Forth Worth, Texas with additional offices in Europe, Asia, and Australia.

DEAL STATS #
Overall 193 of 451
Sector: Life Science M&A 26 of 46
Type: Going Private M&A Deals 28 of 39
State: New Jersey M&A 2 of 5
Country: United States M&A 131 of 298
Year: 2012 M&A 5 of 10
Size (of disclosed) 44 of 113
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-07-05 Taishin

Taipei, Taiwan

Taishin was established upon the completion of the merger between Dah An Commercial Bank and Taishin International Bank. The merger marks the very first voluntary bank merger in Taiwan's history. That same year, Taishin bills finance and Taiwan securities came under the umbrella of Taishin Financial Holdings. Taishin was incorporated in 1992 and is headquartered in Taipei, Taiwan.

Sell $182M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-07-21 Fenwal

Lake Zurich, Illinois, United States

Fenwal, Inc. is one of the world's largest suppliers of products and services to the transfusion medicine industry. Fenwal was created with a single purpose: to provide high quality, innovative blood collection and processing products and services that support customers' missions to improve and save lives.

Sell $1.1B
Mergr

Solution for

Product

Company

Legal